What Eolas Biosciences Co. does

Eolas Biosciences Co. Ltd. is a Japanese pharmaceutical research support company founded in 2005 and headquartered in Matsudo, Japan. The company operates as a hybrid contract research organization (CRO) and specialized technology distributor, delivering in vitro drug discovery products and services to Japanese pharmaceutical and biotech firms. Its core offering is a curated suite of proprietary assay technologies sourced from international partners, including the ToxTracker suite (ToxTracker, MutaTracker, ReproTracker, ToxProfiler, TubulinTracker) from Toxys B.V. (Netherlands), the Opti-Expression transporter assay platform from BioIVT (USA), and the Epiontis ID epigenetic immune monitoring service from Precision for Medicine GmbH (Germany). Eolas adds local-language technical support, regulatory-grade documentation, and project management to enable Japanese clients to use these validated assays in drug discovery and regulatory submissions.

The company's technology portfolio spans genotoxicity and developmental toxicity screening (with ToxTracker adopted as OECD Test Guideline 446A), transporter assays (over 100 established systems), immune monitoring via epigenetic qPCR, ex vivo tumor models (Tru-Tumor), Parkinson's/MASH/NASH/renal disease models, single-cell proteomics (IMC/CODEX, CyTOF), and human biomaterials (tissue, plasma, serum, fresh human islets, IHC database of 550+ drug targets). Eolas monetizes through fee-for-service contract research (CRO project work) and product resale (cell lines, reagents, kits, human tissue samples). Pricing is provided through custom quotations and is not publicly disclosed. The client base is concentrated in Japanese pharmaceutical and biotech R&D organizations, with the company also operating an English-language site signaling exploratory outreach to international clients.

Eolas maintains a network of 35+ technology partners and holds ISO/IEC 27001:2022 / JIS Q 27001:2023 certification for its information security management system. The company has no disclosed funding rounds, no public revenue, and is reported to operate with 1–10 employees. Named customer logos circulating with the Epiontis ID technology (Celgene/BMS, Eli Lilly, Nektar Therapeutics/Oncomed) reflect partner-level deployments rather than direct Eolas customers. The company's strategic posture is that of a stable, niche Japan-focused specialist distributor rather than a high-growth technology platform.

Name

Eolas Biosciences Co.

Legal name

Eolas Biosciences Co. Ltd.

Website

https://eolas-bio.co.jp

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Eolas Biosciences Co. is a Japanese CRO and specialized drug discovery technology distributor founded in 2005 that delivers in vitro toxicology, transporter, immune monitoring, and disease model products and services to Japanese pharmaceutical and biotech clients through a global network of technology partners.

Ownership category

akta.pro rank

Product category

Drug Discovery Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Drug discovery services
• In vitro toxicology
• Contract research organization
• Preclinical safety testing
• Transporter assays

Headquarters

HQ city

Matsudo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Contract Research Services: The company provides contract research services for drug discovery, including toxicity assessment (genotoxicity, developmental toxicity, cytotoxicity), transporter assays, immune monitoring, and human tissue samples. Services are provided through international partner network including Toxys B.V., BioIVT, and Precision for Medicine.
2. Research Products: Sale of specialized products including cell lines, human tissue samples, reagents, and assay kits for pharmaceutical research. Products include GPCR cell lines, immortalized primary cell lines, fluorescent cell lines, and human biomaterials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Eolas Biosciences is a Japan-based contract research organization that distributes and operates partner-developed in vitro drug discovery technologies for Japanese pharmaceutical and biotech companies. The company provides a comprehensive suite of contract research services spanning genotoxicity testing (ToxTracker, MutaTracker), developmental toxicity (ReproTracker), cytotoxicity profiling (ToxProfiler, TubulinTracker), transporter assays (Opti-Expression), and immune monitoring (Epiontis ID), delivered through a global partner network.

Product overview

Eolas Biosciences Co. is a pharmaceutical research support company founded in 2005 that provides cutting-edge products and contract research services for drug discovery. The portfolio consists of multiple technology platforms: ToxTracker, MutaTracker, ToxProfiler, and TubulinTracker for in vitro toxicity assessment; ReproTracker for developmental toxicity; Opti-Expression for transporter assays; Epiontis ID for immune monitoring; disease models (Tru-Tumor, Parkinson's, MASH/NASH, renal); single cell analysis services (IMC/CODEX, CyTOF); human biomaterials including tissue samples and IHC databases; and cell line products. These offerings are delivered primarily as contract research services rather than standalone software products.

Differentiator

Problem solved

Functional benefit

Brands

• Pharma Research Technologies: The company's overarching brand positioning for its drug discovery products and services portfolio.

Products and services

• ToxTracker In vitro genotoxicity assay using six mammalian stem cell lines with GFP reporter genes to identify DNA damage, oxidative stress, protein damage, and p53-mediated cellular stress pathways. OECD TG 446A validated with 94% sensitivity and 95% specificity.
• MutaTracker Combined genotoxicity and mutagenicity assessment system pairing ToxTracker cell lines with error-corrected next-generation sequencing (SMM-seq) to detect low-frequency mutations at 1/10^7 base pair level with 94% sensitivity and 95% specificity.
• ReproTracker Human stem cell-based in vitro developmental toxicity assay differentiating hiPSCs into cardiomyocytes, hepatocytes, and neural cells to assess teratogenicity with 85% sensitivity and 84% specificity.
• ToxProfiler In vitro toxicity profiling technology using seven genetically modified HepG2 cell lines with GFP fusion reporter genes detecting oxidative stress, cell cycle stress, ER stress, autophagy, ion stress, protein stress, and inflammation.
• TubulinTracker In vitro assay using Tubulin-GFP expressing cell lines to evaluate microtubule formation effects and distinguish between tubulin depolymerization and polymerization inhibitors for aneugenicity assessment.
• Opti-Expression Transporter assay technology using mammalian cells with 80%+ transfection efficiency, offering over 100 established transporter assay systems including multi-transporter co-expression models for drug discovery and regulatory submissions.
• Epiontis ID Proprietary epigenetic marker-based immune monitoring service quantifying immune cells in clinical blood and tissue samples via qPCR using demethylated DNA sequences, offering advantages over flow cytometry with frozen sample compatibility.
• Tru-Tumor Ex vivo Tumor Model Ex vivo tumor model using human cancer tissue that preserves tumor diversity and microenvironment for cancer research and drug discovery applications.
• Parkinson's Disease Models Contract research services for Parkinson's disease research using primate and rodent models, including proprietary models developed by Atuka Inc.
• Single Cell Analysis (IMC/CODEX, CyTOF) Single cell analysis services enabling simultaneous quantification of up to 50 proteins per cell from tissue samples or cell suspensions using IMC/CODEX and CyTOF platforms.
• Human Biomaterials Human tissue, plasma, serum, and body fluid samples for research, including custom procurement of clinical specimens, fresh human islets with specialized media, and IHC database covering over 550 drug targets.
• Cell Lines GPCR cell lines, immortalized primary cell lines, stable fluorescent cell lines, and custom cell line development services for pharmaceutical research applications.

Quantifiable outcome

• Genotoxicity prediction accuracy: 94% sensitivity, 95% specificity
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Three partnerships are on record, tiered core.

• BioIVT LLCcoreTechnology or IntegrationLeading US provider of research samples and models. BioIVT developed Opti-Expression transporter assays offered by Eolas. Over 1,000 contract research projects completed since 2007.
• Precision for Medicine GmbHcoreTechnology or IntegrationGerman company that developed Epiontis ID technology for immune monitoring. Eolas distributes their epigenetic immune cell counting technology in Japan. Over 68,000 samples analyzed from 100+ clinical trials.
• Toxys B.V.coreTechnology or IntegrationDutch company that developed ToxTracker (OECD TG 446A), ToxProfiler, ReproTracker, MutaTracker, and TubulinTracker assays. Eolas distributes their full suite of in vitro toxicity assessment technologies in Japan.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Others

• Toxys B.V. ToxTracker's technology developer and Eolas's core partner. While not a commercial peer, Toxys is the upstream technology owner whose products Eolas resells in Japan — relevant for understanding competitive dynamics if Toxys establishes direct Japan presence.
• BioIVT LLC: US-headquartered provider of research samples, transporter assays (Opti-Expression developer), and biospecimens — and Eolas's core partner with 1,000+ joint projects since 2007. Not a commercial peer but a strategic partner whose go-to-market choices directly affect Eolas.
• Precision for Medicine GmbH: Developer of Epiontis ID immune monitoring technology and Eolas's core partner for clinical biomarker services in Japan — relevant as both a partner and potential direct competitor if it expands into Japan independently.

Direct peers

• Cosmo Bio Co., Ltd. Japanese life science reagent and research product distributor with deep relationships to global suppliers — a directly comparable distributor/aggregator business model serving the same Japanese pharma research customer base.
• Reprocell Inc. Japanese stem cell and CRO company offering drug discovery support services including iPSC-based assays, contract research, and biosamples — directly comparable to Eolas's ReproTracker and biomaterials offerings for Japanese pharma clients.
• Funakoshi Co., Ltd. Long-established Japanese distributor of life science research reagents, cell lines, and assay kits from international suppliers — closely mirrors Eolas's role as a Japan gateway for global biotech research products.

Emerging players

• Crown Bioscience Inc. Global provider of in vitro and in vivo disease models for oncology and metabolic disease drug discovery — listed as one of Eolas's partners but also a potential alternative vendor for Japanese pharma preclinical programs.

Broad incumbents

• Eurofins Scientific SE: Large global CRO with broad in vitro toxicology, biomarker, and clinical sample testing capabilities that operates in Japan — represents the broader competitive set Eolas faces when Japanese sponsors outsource preclinical safety work.
• Charles River Laboratories International, Inc. Global CRO offering in vitro toxicology, safety assessment, and discovery services with established Japan operations — represents the scale-incumbent competitive threat for Japanese pharma preclinical CRO budgets.

Regional players

• Sumitomo Bakelite Co., Ltd. (PhoenixBio / S-BIO Business): Japanese life sciences business with subsidiary PhoenixBio offering human hepatocyte and liver toxicity CRO services — a Japanese-based in vitro toxicology CRO that competes for similar preclinical safety budgets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eolas-biosciences-co.-ltd.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eolas Biosciences Co.